Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

Published:2022-04-01 Issue:4 Volume:8 Page:597
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Dai Wei Fang¹²,Beca Jaclyn M.²³,Nagamuthu Chenthila⁴,Liu Ning⁴,de Oliveira Claire⁴⁵,Earle Craig C.⁴,Trudeau Maureen⁶,Chan Kelvin K. W.¹²³⁶

Affiliation:

1. Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada

3. Ontario Health, Ontario, Canada

4. ICES, Ontario, Canada

5. Centre for Health Economics and Hull York Medical School, University of York, York, United Kingdom

6. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2789386/jamaoncology_dai_2022_oi_210108_1650482084.43724.pdf

Reference50 articles.

1. Examining trends in cost and clinical benefit of novel anticancer drugs over time.;Saluja;J Oncol Pract,2018

2. Projections of the cost of cancer care in the United States: 2010-2020.;Mariotto;J Natl Cancer Inst,2011

3. The economic burden of cancer care in Canada: a population-based cost study.;de Oliveira;CMAJ Open,2018

4. Phase-specific and lifetime costs of cancer care in Ontario, Canada.;de Oliveira;BMC Cancer,2016

5. Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.;de Oliveira;CMAJ Open,2013

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;ESMO Open;2024-09

2. Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON);Clinical Cancer Research;2024-07-19

3. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;British Journal of Cancer;2024-06-21

4. Common Sense Oncology: Equity, Value, and Outcomes That Matter;American Society of Clinical Oncology Educational Book;2024-06

5. Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020;Breast Cancer Research and Treatment;2023-12-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3